Skip to main content
. 2023 Jan 19;18(2):555–569. doi: 10.1016/j.stemcr.2022.12.014

Figure 1.

Figure 1

MMP activity-based drug screen

(A) Overview of differentiation to NC-VSMCs from iPSCs.

(B) MFS VSMCs were treated with 1 μM SMIs for 96 h and cell supernatant collected. This supernatant contains secreted MMPs, which, when incubated with the generic MMP substrate, leads to cleavage and a subsequent fluorescent signal, which can be measured using a plate reader.

(C) Of the 1,022 SMIs, the majority were not suitable for further assay at 1 μM.

(D) Among the SMIs used in the screen, 36 were found to decrease MMP activity of MFS VSMCs.

Corrected VSMCs and MFS VSMCs treated with losartan were used as controls to determine the threshold of sufficient MMP activity reduction. Drug screen was performed as n = 2 technical replicates.